Scientists have introduced a microscopy technique that reveals a hidden layer of chemistry involving molecules that normally evade detection.
Category: innovation
Mesothelioma: a systemic therapy clinical trials snapshot
Systemic therapy targets in mesothelioma.
Recent changes to clinical practice have made modest improvements in 1– 2-year survival, but longer-term survival remains unchanged, and durable benefit is very rare.
Combining immunotherapy with chemotherapy, particularly with novel bispecific agents, may result in more therapeutic modalities being administered together in the first-line setting. The current evidence for second-line treatments is sparse.
New targeted-therapy strategies are promising. Early-phase clinical trials are showing signals of efficacy in mesotheliomas harboring MTAP loss or inactivation of the Hippo pathway.
Further studies will be needed to robustly confirm clinical benefit. sciencenewshighlights ScienceMission https://sciencemission.com/Mesothelioma
Mesothelioma is a rare cancer that has seen few incremental improvements in survival over the past two decades. However, a significantly improved understanding of the underlying biology has led to new therapeutic advances with the potential to improve clinical outcomes. In this review, we take a snapshot of the current systemic therapy research landscape, with our goal to forecast the trajectory of drug development for mesothelioma over the next half-decade. In our current census, we identify 106 active trials including systemic therapies: 20 (19%) are molecularly targeted, 26 (25%) include immunomodulation, and 12 (11%) combining immunotherapy with antiangiogenic therapies. Collectively, the landscape of therapeutic innovation for mesothelioma is expanding, bringing hope that improvements in life expectancy may follow.
Mineral and bone effects of EPT
Highlighting the potential of PTH1R receptor agonist therapy in autosomal dominant hypocalcemia type 1
https://doi.org/10.1172/JCI201759 In this Research Letter, Rajesh V. Thakker & team report on the use of Eneboparatide in mice with ADH1, which increased serum calcium levels without increasing urine calcium.
3Mary Lyon Centre, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, United Kingdom.
4Endocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
5William Harvey Research Institute, London School of Medicine, Queen Mary University of London, London, United Kingdom.
Invention XX, by Shawn Bell
From networks XII: inventions & invocations by.
Shawn Bell
Microscopic mechanism of ‘quantum collapse’ in real-world environments uncovered for the first time
A research team has, for the first time in the world, elucidated the microscopic mechanism by which quantum order is lost and collapses in “open quantum environments” existing in nature. Since perfectly isolated quantum systems cannot exist in reality, this study is expected to provide a decisive breakthrough in bridging the gap between ideal quantum theory and quantum technologies that must operate in real-world environments.
The study is published in the journal Advanced Science. The study was led by Professor JaeDong Lee of the Department of Physics and Chemistry at DGIST.
The Future of Transplants: Stopping Rejection Before It Starts — Dr. Janine Gaiha-Rohrbach — Biogen
Dr. Janine Gaiha-Rohrbach, Ph.D. — Head of Global Medical Immunology, Biogen.
Preventing transplant loss doesn’t just save organs—it could eliminate hospitalizations, reduce lifelong medications, and transform millions of lives.
Dr. Janine Gaiha-Rohrbach, Ph.D. is a globally recognized leader in immunology and medical strategy, currently serving as Head of Global Medical Immunology at Biogen (https://www.biogen.com/).
With a PhD in Immunology and Virology from the University Hospital of Berne and extensive postdoctoral research at the Ragon Institute of Mass General Brigham, MIT, and Harvard, Dr. Gaiha-Rohrbach has dedicated her career to translating complex scientific advances into high-impact patient care.
Throughout her career, Dr. Gaiha-Rohrbach has driven innovation across diverse therapeutic areas, including HIV, hepatitis, NASH, and specialized immunology, leading multiple new product launches and shaping global strategies to expand patient access.
New synthetic origin of replication lets multiple plasmids coexist in one bacterial cell
“If it ain’t broke, don’t fix it,” goes the old adage, which Rice University professor James Chappell completely ignored in a recent Nature Communications publication. In the study, Chappell describes an innovation in plasmids, circular pieces of DNA that have been a workhorse of molecular biology research since the 1970s.
“For decades, we’ve been designing experiments around two major limitations of plasmids: fixed copy numbers and incompatibility,” said Chappell, the corresponding author on the study. “While functional, such workarounds are clunky. We created a synthetic version of a part of the plasmid called the origin of replication that allows us to modify the plasmid instead of modifying the experiment.”
Plasmids are typically put into bacterial cells, where they use the cell’s machinery to build proteins and create copies of themselves. Each plasmid generates tiny pieces of a stop signal, called a negative regulator, which binds to the origin of replication (ORI).
This Multidimensional Holographic Breakthrough Stores Massive Data Inside Light Itself
A breakthrough holographic system uses AI and multidimensional light to store vastly more data in less space.
